Chinese Rare Disease-Focused Biotech Startup Citrine Medicine Raises US$80M Series A

Citrine Medicine aims to develop an ecosystem for rare disease patients in China

Citrine Medicine, a Chinese rare disease-focused therapeutics startup founded by Eight Roads, F-Prime Capital, and Vivo Capital, has raised $80 million in a Series A funding round, according to a press release on Monday.

The latest financing round was led by Quan Capital, a medical and healthcare-focused venture capital firm, while new investors 3H Health Investment and WU Capital also participated in the round along with the three founding backers.

The startup, which imports rare disease medicines to China, aims to deliver these drugs to the Chinese market and develop the first ever rare disease ecosystem in the country, with the prospect of helping tens of millions of patients, according to the press release.

With 20 million people suffering from rare diseases in Mainland China, and none eligible for free treatment, the market holds untapped potential for Citrine as the current treatment options are unaffordable for the majority of patients in need. Moreover, these diseases are often difficult to diagnose, difficult to treat, and difficult to guarantee recovery, according to the press report.

Since its inception in 2019, Citrine has assembled a best-in-class team of veterans with decades of work experience in rare diseases and the healthcare market in China, according to the press report.

Rebecca Lin, Partner of Eight Roads and a director of Citrine’s Board, said, “Citrine is dedicated to bringing in safe and effective medications to patients in China suffering from rare diseases. Our aspiration is to build an ecosystem of support for the patients, working together with various stakeholders to fundamentally remove the accessibility and affordability obstacles.”

Recent reforms in regulation and policy in China have expedited the drug approval process for rare disease drugs. These new regulations allow rare-disease drugs, also called orphan drugs, to be submitted for approval in China with only overseas clinical trial data.

According to the statement, Citrine will focus on validated or approved medications, while at the same time helping products speed up their development processes globally.

“Citrine is a unique platform which can leverage the resources of all investors and benefits from the synergy of this extensive network, including Eight Roads’ global resources and connections. We believe Citrine is well-positioned to build something meaningful for the rare disease community,” Lin added.

F-Prime’s Principal, Dr. Chong Xu said, “F-Prime Capital is a strong believer and long-time investor in companies developing drugs for orphan disease patients in need. We helped found Citrine because we were excited about the potential for the company to significantly improve the lives of patients and families in China affected by rare diseases.”

Dr. Wu Hui, Managing Director of Quan Capital, said, “We look forward to providing strong support for Citrine’s capabilities and pipelines in terms of talent recruitment, local operating resources, and overseas product cooperation. With the strong support of investors, we are confident that Citrine will become a leader in this field and accelerate the development of innovative rare disease drugs in China and globally.”

Header image by Volodymyr Hryshchenko on Unsplash

SHARE THIS STORY

Share on facebook
Share on twitter
Share on linkedin
Share on email

RELATED POSTS

Essential Privacy Tools to Safeguard Your Devices

Essential Privacy Tools to Safeguard Your Devices

In the ever-expanding digital era, protecting sensitive information and ensuring data security has become paramount. According to a recent study conducted by MAGNA’s Media Trials unit and data governance platform Ketch, a staggering 74 percent of individuals say that data privacy is one of their top concerns.

4 Reasons Why India's EV Industry is Poised for Rapid Growth

4 Reasons Why India’s EV Industry is Poised for Rapid Growth

Hold on to your seats, because India’s electric vehicle (EV) industry is not just gaining speed—it’s shifting gears faster than a Tesla Roadster on Ludicrous mode. EVs are no longer just futuristic fantasies; they’re already ruling the roads of Delhi and zooming past their counterparts fueled by fossil fuels on the highways of Mumbai.

Microsoft-backed Builder.ai Secures Over US$250 Million in Series D Funding

Microsoft-backed Builder.ai Secures Over US$250 Million in Series D Funding

London-based artificial intelligence (AI)-powered composable software platform Builder.ai has raised a significant investment of over US$250 million in Series D funding. Led by Qatar Investment Authority (QIA), the funding round brings the total amount raised by the company to over US$450 million, resulting in a valuation increase of up to 1.8x.

Essential Gaming Slang Terms for True Gamers

Essential Gaming Slang Terms for True Gamers

Gaming is not just a hobby; it’s a culture with its own unique language. Understanding slang and jargon is crucial for having an immersive experience and connecting with fellow gamers. From the acronyms that define player roles to the phrases that capture epic moments, mastering these slang terms is a must for every true gamer.

LinkedIn Launches Tools to Boost Job Seekers' Safety and Confidence

LinkedIn Launches Tools to Boost Job Seekers’ Safety and Confidence

Networking platform LinkedIn has introduced a range of tools to empower job seekers to confidently navigate their job search process while ensuring their safety and security. The latest updates include the implementation of verifications on job posts, enabling the display of verified information about job posters or their companies.